<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03036384</url>
  </required_header>
  <id_info>
    <org_study_id>NB076201627436</org_study_id>
    <nct_id>NCT03036384</nct_id>
  </id_info>
  <brief_title>Estimation of the ED95 of Intrathecal Hyperbaric Prilocaine 2% With Sufentanyl for Scheduled Cesarean Delivery</brief_title>
  <official_title>Estimation of the ED95 of Intrathecal Hyperbaric Prilocaine 2% With Sufentanyl for Scheduled Cesarean Delivery : a Dose-finding Study Bases on the Continual Reassessment Method (CRM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Saint Pierre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperbaric bupivacaine 0.5% associated with opioids is the local anesthetic the most commonly
      used for spinal injection in cesarean section. Nevertheless, its use often results in a long
      duration of motor nerve block and a haemodynamical instability. Recently developped, the
      Prilocaine, with its new 2% hyperbaric formulation, seems to offer a good alternative for
      hyperbaric bupivicaine. A first study has determined the ED95 of hyperbaric prilocaine 2% for
      intrathecal anesthesia in scheduled cesarean delivery. As opioid adjuvants potentiate the
      effect of the local anesthetics while decreasing their dose-related side effects, the aim of
      this study is to determine the ED95 of hyperbaric prilocain 2% with sufentanyl for scheduled
      cesarean delivery under spinal anesthesia,by using the Continual Reassessment Method (CRM)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of anesthesia</measure>
    <time_frame>during surgery (average 1 hour)</time_frame>
    <description>The nerve blockade will be considered as success when a bilateral T4 level will reach in 15 minutes after intrathecal injection without additional epidural injection needed within 45 minutes peri-operative ; no pain at the skin incision, no pain during 45 minutes after the skin incision</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2. Level of Sensory block assessed as loss of sensation to pinprick, cold and pressure</measure>
    <time_frame>Until complete release of sensory block (T12-S1) (average 4 hours)</time_frame>
    <description>Every 2 minutes after spinal anesthesia during 15 minutes, then every 5 minutes until the end of surgery, thereafter, once 30 minutes until total regression of sensory block (T12-S1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side-effects (nausea, vomiting,prurit)</measure>
    <time_frame>up to 24 hours after surgery</time_frame>
    <description>from 15 minutes after spinal anesthesia and every 4 hours for 24 hours (score 0=no symptoms; 1=symptoms with no treatment necessary; 2=symptoms present and treated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Neurologic Symptoms (TNS)</measure>
    <time_frame>up to 5 Days</time_frame>
    <description>TNS are defined as pain and/or dysesthesia occurred after complete release of sensory block at the gluteal level, at the tighs and at the legs. At Day 0, Day 1, Day 3 and Day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by Visual Analog Scale</measure>
    <time_frame>up to 24 hours after surgery</time_frame>
    <description>Pain levels will be determined at incision, baby delivery, peritoneal and skin closure, every 5 minutes during surgery, and thereafter every 4 hours for 24 hours. Visual Analog pain score (scale = 0 no pain; 10= worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with low blood pressure</measure>
    <time_frame>during surgery (average 1 hour)</time_frame>
    <description>Arterial blood pressure will be measured at every 2.5 minute during surgery, then at every 20 minutes in the PACU (Post Anesthesia Care Unit). A blood pressure lower is define as a blood pressure lower than 20% or more than the basal blood pressure (Systolic blood pressure before spinal anesthesia)</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pregnant Women</condition>
  <arm_group>
    <arm_group_label>Cohort 1 : HB prilocaine 2%, 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 10 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB Prilocaine 2% (varying dose)</intervention_name>
    <description>Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of 60mg of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 5µg of sufentanyl</description>
    <arm_group_label>Cohort 2 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 3 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 4 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 5 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 6 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 7 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 8 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 9 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 10 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <other_name>Tachipri</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB Prilocaine 2%</intervention_name>
    <description>The dose of 60mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 5µg of sufentanyl</description>
    <arm_group_label>Cohort 1 : HB prilocaine 2%, 60mg</arm_group_label>
    <other_name>Tachipri</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>5µg sufentanyl</description>
    <arm_group_label>Cohort 1 : HB prilocaine 2%, 60mg</arm_group_label>
    <arm_group_label>Cohort 2 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 3 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 4 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 5 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 6 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 7 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 8 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 9 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 10 : HB prilocaine 2%, (45-70mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>100 µgMorphine</description>
    <arm_group_label>Cohort 1 : HB prilocaine 2%, 60mg</arm_group_label>
    <arm_group_label>Cohort 2 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 3 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 4 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 5 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 6 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 7 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 8 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 9 : HB prilocaine 2%, (45-70mg)</arm_group_label>
    <arm_group_label>Cohort 10 : HB prilocaine 2%, (45-70mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists physical status (ASA) &lt; III

          -  Age 18-40 year

          -  Body Weight &lt;100 kg

          -  Height between 160 and 175 cm

          -  Gestational age&gt;37 SA

          -  Elective cesarean delivery

          -  Singleton pregnancy

          -  Non complicated pregnancy

          -  Signed informed consent obtained prior to any study specific assessments and
             procedures

        Exclusion Criteria:

          -  Twin pregnancy

          -  History of 2 cesarean section or more

          -  Diabetes and gestational diabetes

          -  Placenta praevia

          -  Congenital foetale abnormality

          -  Patient in labour

          -  Membrane rupture

          -  Known allergy to local anaesthetics

          -  Disagreement of the patient

          -  Pregnancy-induced hypertension

          -  Pre eclampsia and eclampsia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Panayota Kapessidou, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Saint-Pierre (CHU Saint-Pierre), Université Libre de Bruxelles (ULB)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Goffard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Saint-Pierre (CHU Saint-Pierre), Université Libre de Bruxelles (ULB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Saint-Pierre, Université Libre de Bruxelles (ULB)</name>
      <address>
        <city>Brussels Capital Region</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Camponovo C, Fanelli A, Ghisi D, Cristina D, Fanelli G. A prospective, double-blinded, randomized, clinical trial comparing the efficacy of 40 mg and 60 mg hyperbaric 2% prilocaine versus 60 mg plain 2% prilocaine for intrathecal anesthesia in ambulatory surgery. Anesth Analg. 2010 Aug;111(2):568-72. doi: 10.1213/ANE.0b013e3181e30bb8. Epub 2010 Jun 7.</citation>
    <PMID>20529983</PMID>
  </reference>
  <reference>
    <citation>Gupta PK, Chevret S, Zohar S, Hopkins PM. What is the ED95 of prilocaine for femoral nerve block using ultrasound? Br J Anaesth. 2013 May;110(5):831-6. doi: 10.1093/bja/aes503. Epub 2013 Feb 7.</citation>
    <PMID>23393153</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2017</study_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>scheduled cesarean delivery</keyword>
  <keyword>spinal anesthesia</keyword>
  <keyword>local anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

